ReviewAdvances in biological regulation2019
Noncoding RNA genes in cancer pathogenesis.
Review in Advances in biological regulation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Integrated miRNA-Target Gene Analysis Reveals Complementary Molecular Biomarkers and Regulatory Networks in Pediatric Neuroblastoma.International journal of molecular sciences · 2026Article
- Venetoclax for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: Prospects, resistance mechanisms and management strategies.Clinical and translational medicine · 2026Review
- tRNA-derived fragments (tRFs) as key non-coding players in the tumor transcriptome of colorectal cancer: introducing a new suspect responsible for the remaining unknowns of tumor pathology.Medical oncology (Northwood, London, England) · 2025Review
- Therapeutic advances in the targeting of ROR1 in hematological cancers.Cell death discovery · 2024Review
- Expression signature of human endogenous retroviruses in chronic lymphocytic leukemia.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Nucleic Acids in Cancer Diagnosis and Therapy.Cancers · 2023Article
- tRNA-derived fragments (tRFs) in cancer.Journal of cell communication and signaling · 2023Review
- Effects of hsa-miR-9-3p and hsa-miR-9-5p on Topoisomerase IIThe Journal of pharmacology and experimental therapeutics · 2023Article
- Small Non-Coding RNAs in Leukemia.Cancers · 2022Review
- Non-Coding RNAs: The "Dark Side Matter" of the CLL Universe.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Mechanisms Governing Metabolic Heterogeneity in Breast Cancer and Other Tumors.Frontiers in oncology · 2021Review
- Long noncoding RNA LINC01124 activates hepatocellular carcinoma cell proliferation, migration, and invasion by absorbing microRNA-1247-5p and overexpressing FOXO3.Oncology research · 2021Article
- Nucleic Acids in Cancer Diagnosis and Therapy.Cancers · 2020Article
- LncRNA ROR1‑AS1 high expression and its prognostic significance in liver cancer.Oncology reports · 2020Article
- The microRNA212 regulated PEA15 promotes ovarian cancer progression by inhibiting of apoptosis.Journal of Cancer · 2020Article
- MicroRNA dysregulation and multi-targeted therapy for cancer treatment.Advances in biological regulation · 2020Review
- CDP-Diacylglycerol Synthases (CDS): Gateway to Phosphatidylinositol and Cardiolipin Synthesis.Frontiers in cell and developmental biology · 2020Review
- TOB1-AS1 suppresses non-small cell lung cancer cell migration and invasion through a ceRNA network.Experimental and therapeutic medicine · 2019Article
- MicroRNAs and their involvement in T-ALL: A brief overview.Advances in biological regulation · 2019Review
- A network-based analysis for mining the risk pathways in glioblastoma.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
By using chronic lymphocytic leukemia as target for discovery in cancer pathogenesis we discovered that the great majority of CLLs (75-85%) carry a deletion of miR-15a and miR-16-1 at 13q14. We also discovered that miR-15/16 are negative regulators of the BCL2 oncogene. Thus the loss of the two negative regulators causes BCL2 overexpression and leukemia. A corollary of this is that CLL is very sensitive to the anti BCL2 drug venetoclax that can induce complete remission in CLL patients. Since leukemia patients may carry billions of leukemia cells, it is quite likely that some (few) of the leukemic cells are resistant to venetoclax. Thus, since microRNAs have multiple targets, we looked for other proteins that may be overexpressed in CLL because of the low of miR-15/16. We discovered that ROR1 an embryonal antigen expressed on most (∼ 90%) CLL, but not on normal B cell, is also regulated by miR-15/16. Thus CLL cells are also sensitive to monoclonal antibodies against ROR1. Venetoclax and monoclonal antibodies against ROR1 act synergistically in killing CLL cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.